Ginkgolic acid C15:1

Ginkgolic acid C15:1
Product Name Ginkgolic acid C15:1
CAS No.: 22910-60-7
Catalog No.: CFN90161
Molecular Formula: C22H34O3
Molecular Weight: 346.50 g/mol
Purity: >=98%
Type of Compound: Phenols
Physical Desc.: Powder
Targets: PI3K | Akt | mTOR | TGF-β/Smad | Antifection
Source: The leaves of Ginkgo biloba L.
Solvent: Chloroform, Dichloromethane, Ethyl Acetate, DMSO, Acetone, etc.
Price: $118/20mg
Ginkgolic acid C15:1 has antibacterial, antiparasitic, and anti-cancer activities, it can suppress lung cancer invasion and migration through the inhibition of PI3K/Akt/mTOR signaling pathway.
Inquire / Order: manager@chemfaces.com
Technical Inquiries: service@chemfaces.com
Tel: +86-27-84237783
Fax: +86-27-84254680

Address:
1 Building, No. 83, CheCheng Rd., Wuhan Economic and Technological Development Zone, Wuhan, Hubei 430056, PRC
Providing storage is as stated on the product vial and the vial is kept tightly sealed, the product can be stored for up to 24 months(2-8C).

Wherever possible, you should prepare and use solutions on the same day. However, if you need to make up stock solutions in advance, we recommend that you store the solution as aliquots in tightly sealed vials at -20C. Generally, these will be useable for up to two weeks. Before use, and prior to opening the vial we recommend that you allow your product to equilibrate to room temperature for at least 1 hour.

Need more advice on solubility, usage and handling? Please email to: service@chemfaces.com

The packaging of the product may have turned upside down during transportation, resulting in the natural compounds adhering to the neck or cap of the vial. take the vial out of its packaging and gently shake to let the compounds fall to the bottom of the vial. for liquid products, centrifuge at 200-500 RPM to gather the liquid at the bottom of the vial. try to avoid loss or contamination during handling.
  • Evid Based Complement Alternat Med.2021, 2021:5585692.
  • Korean Journal of Plant Resources2021, 34(1):52-58.
  • Nat Prod Sci.2018, 24(3):206
  • Evid Based Complement Alternat Med.2018, 2018:8565132
  • Phytother Res.2018, 32(12):2551-2559
  • J Appl Biol Chem2021, 64(3):245-251.
  • Nutr Res Pract.2020, 14(3):203-217.
  • Front Aging Neurosci.2018, 10:269
  • Biomedicines.2021, 9(8):996.
  • J Nat Med.2018, 72(3):734-744
  • Grifolic acid

    Catalog No: CFN97284
    CAS No: 80557-12-6
    Price: Inquiry(manager@chemfaces.com)
    Cytosporone B

    Catalog No: CFN90885
    CAS No: 321661-62-5
    Price: $318/10mg
    2'-O-Methylperlatolic acid

    Catalog No: CFN98621
    CAS No: 38968-07-9
    Price: Inquiry(manager@chemfaces.com)
    Confluentic acid

    Catalog No: CFN97015
    CAS No: 6009-12-7
    Price: Inquiry(manager@chemfaces.com)
    Bongardol

    Catalog No: CFN99352
    CAS No: 123690-76-6
    Price: Inquiry(manager@chemfaces.com)
    9-Deoxygoniopypyrone

    Catalog No: CFN96020
    CAS No: 136685-37-5
    Price: Inquiry(manager@chemfaces.com)
    Goniopypyrone

    Catalog No: CFN96048
    CAS No: 129578-07-0
    Price: Inquiry(manager@chemfaces.com)
    Ginkgolic acid C13:0

    Catalog No: CFN98507
    CAS No: 20261-38-5
    Price: $168/20mg
    Ginkgolic acid C15:0

    Catalog No: CFN90339
    CAS No: 16611-84-0
    Price: Inquiry(manager@chemfaces.com)
    Ginkgolic acid C15:1

    Catalog No: CFN90161
    CAS No: 22910-60-7
    Price: $118/20mg
    Int J Food Microbiol. 2014 Mar 17;174:47-55.
    Ginkgolic acids and Ginkgo biloba extract inhibit Escherichia coli O157:H7 and Staphylococcus aureus biofilm formation.[Pubmed: 24457153]
    Infection by enterohemorrhagic Escherichia coli O157:H7 (EHEC) is a worldwide problem, and there is no effective therapy. Biofilm formation is closely related to EHEC infection and is also a mechanism of antimicrobial resistance.
    METHODS AND RESULTS:
    Antibiofilm screening of 560 purified phytochemicals against EHEC showed that Ginkgolic acid C15:1 and ginkgolic acid C17:1 at 5μg/ml and Ginkgo biloba extract at 100μg/ml significantly inhibited EHEC biofilm formation on the surfaces of polystyrene and glass, and on nylon membranes. Importantly, at their working concentrations, ginkgolic acids and G. biloba extract did not affect bacterial growth. Transcriptional analyses showed that Ginkgolic acid C15:1 repressed curli genes and prophage genes in EHEC, and these findings were in-line with reduced fimbriae production and biofilm reductions. Interestingly, ginkgolic acids and G. biloba extract did not inhibit the biofilm formation of a commensal E. coli K-12 strain. In addition, ginkgolic acids and G. biloba extract inhibited the biofilm formation of three Staphylococcus aureus strains.
    CONCLUSIONS:
    The findings of this study suggest that plant secondary metabolites represent an important resource for biofilm inhibitors.
    BMC Biotechnol. 2017; 17: 5.
    The antibacterial activity and mechanism of ginkgolic acid C15:1.[Pubmed: 28088196]
    The present study investigated the antibacterial activity and underlying mechanisms of Ginkgolic acid C15:1(GA (C15:1)) monomer using green fluorescent protein (GFP)-labeled bacteria strains.
    METHODS AND RESULTS:
    GA presented significant antibacterial activity against Gram-positive bacteria but generally did not affect the growth of Gram-negative bacteria. The studies of the antibacterial mechanism indicated that large amounts of GA (C15:1) could penetrate GFP-labeled Bacillus amyloliquefaciens in a short period of time, and as a result, led to the quenching of GFP in bacteria. In vitro results demonstrated that GA (C15:1) could inhibit the activity of multiple proteins including DNA polymerase. In vivo results showed that GA (C15:1) could significantly inhibit the biosynthesis of DNA, RNA and B. amyloliquefaciens proteins.
    CONCLUSIONS:
    We speculated that GA (C15:1) achieved its antibacterial effect through inhibiting the protein activity of B. amyloliquefaciens. GA (C15:1) could not penetrate Gram-negative bacteria in large amounts, and the lipid soluble components in the bacterial cell wall could intercept GA (C15:1), which was one of the primary reasons that GA (C15:1) did not have a significant antibacterial effect on Gram-negative bacteria.
    Toxicol Appl Pharmacol . 2018 Apr 15;345:1-9.
    Pharmacological inhibition of SUMO-1 with ginkgolic acid alleviates cardiac fibrosis induced by myocardial infarction in mice[Pubmed: 29524504]
    Abstract Background and purpose: Protein modification by small ubiquitin-like modifier (SUMO) plays a critical role in the pathogenesis of heart diseases. The present study was designed to determine whether ginkgolic acid (GA) as a SUMO-1 inhibitor exerts an inhibitory effect on cardiac fibrosis induced by myocardial infarction (MI). Experimental approach: GA was delivered by osmotic pumps in MI mice. Masson staining, electron microscopy (EM) and echocardiography were used to assess cardiac fibrosis, ultrastructure and function. Expression of SUMO-1, PML, TGF-β1 and Pin1 was measured with Western blot or Real-time PCR. Collagen content, cell viability and myofibroblast transformation were measured in neonatal mouse cardiac fibroblasts (NMCFs). Promyelocytic leukemia (PML) protein was over-expressed by plasmid transfection. Key results: GA improved cardiac fibrosis and dysfunction, and decreased SUMO-1 expression in MI mice. GA (>20 μM) inhibited NMCF viability in a dose-dependent manner. Nontoxic GA (10 μM) restrained angiotensin II (Ang II)-induced myofibroblast transformation and collagen production. GA also inhibited expression of TGF-β1 mRNA and protein in vitro and in vivo. GA suppressed PML SUMOylation and PML nuclear body (PML-NB) organization, and disrupted expression and recruitment of Pin1 (a positive regulator of TGF-β1 mRNA), whereas over-expression of PML reversed that. Conclusions and implications: Inhibition of SUMO-1 by GA alleviated MI-induced heart dysfunction and fibrosis, and the SUMOylated PML/Pin1/TGF-β1 pathway is crucial for GA-inhibited cardiac fibrosis.
    Aquaculture, 2009, 297(1-4):38-43.
    In vivo assessment of anthelmintic efficacy of ginkgolic acids (C13:0, C15:1) on removal of Pseudodactylogyrus in European eel.[Reference: WebLink]
    Pseudodactylogyrus is a significant monogenean parasite of the gills of aquacultured European eels, and can cause severe gill pathology.
    METHODS AND RESULTS:
    In this study, effects of the crude extracts, fractions and compounds of exopleura of Ginkgo biloba against Pseudodactylogyrus were investigated under in vivo conditions by bio-assay guided isolation method. Four solvents (petroleum ether, ethyl acetate, n-butanol and water) were applied for the extraction of exopleura of G. biloba. Among them, only the petroleum ether extract showed strong activity and therefore, subjected to further separation and purification using various chromatographic techniques. Two compounds showing potent activity were identified by comparing spectral data (IR, NMR, and EI-MS) with literature values to be ginkgolic acid C13:0 and Ginkgolic acid C15:1. They were found to be 100% effective at the concentration of 2.5mg l⁻1 and 6.0mg l⁻1, with ED₅₀ values of 0.72mg l⁻1 and 2.88mg l⁻1, respectively. In the 5-days safety test, ginkgolic acid C13:0 and Ginkgolic acid C15:1 were shown to be safe for healthy juvenile eels when the concentration were up to 10.0 and 18.0mg l⁻1, respectively.
    CONCLUSIONS:
    The two compounds exhibited potential results and can be explored as plant-derived antiparasitic for the control of Pseudodactylogyrus.
    J Cell Physiol. 2017 Feb;232(2):346-354.
    Ginkgolic Acid Inhibits Invasion and Migration and TGF-β-Induced EMT of Lung Cancer Cells Through PI3K/Akt/mTOR Inactivation.[Pubmed: 27177359]
    Epithelial-to-mesenchymal transition (EMT) is a critical cellular phenomenon regulating tumor metastases.
    METHODS AND RESULTS:
    In the present study, we investigated whether ginkgolic acid can affect EMT in lung cancer cells and the related underlying mechanism(s) of its actions. We found that Ginkgolic acid C15:1 (GA C15:1) inhibited cell proliferation, invasion, and migration in both A549 and H1299 lung cancer cells. GA C15:1 also suppressed the expression of EMT related genes (Fibronectin, Vimentin, N-cadherin, MMP-9, MMP-2, Twist and Snail) and suppressed TGF-β-induced EMT as assessed by reduced expression of mesenchymal markers (Fibronectin, Vimentin, N-cadherin), MMP-9, MMP-2, Twist and Snail. However, GA C15:1 did not affect the expression of various epithelial marker proteins (Occludin and E-cadherin) in both A549 and H1299 cells. TGF-β-induced morphologic changes from epithelial to mesenchymal cells and induction of invasion and migration were reversed by GA C15:1. Finally, GA C15:1 not only abrogated basal PI3K/Akt/mTOR signaling cascade, but also reduced TGF-β-induced phosphorylation of PI3K/Akt/mTOR pathway in lung cancer cells.
    CONCLUSIONS:
    Overall, these findings suggest that GA C15:1 suppresses lung cancer invasion and migration through the inhibition of PI3K/Akt/mTOR signaling pathway and provide a source of potential therapeutic compounds to control the metastatic dissemination of tumor cells.
    Bergaptol-beta-glucopyranoside

    Catalog No: CFN95186
    CAS No: 131623-13-7
    Price: $318/10mg
    Isovalerylshikonin

    Catalog No: CFN95222
    CAS No: 52387-14-1
    Price: $318/10mg
    Nortrachelogenin-5'-C-beta-glucoside

    Catalog No: CFN95251
    CAS No: 858127-39-6
    Price: $318/10mg
    Rosmarinyl glucoside

    Catalog No: CFN95297
    CAS No: 910028-78-3
    Price: $413/5mg
    New compound 14

    Catalog No: CFN95381
    CAS No: N/A
    Price: $413/5mg
    Annphenone

    Catalog No: CFN95426
    CAS No: 61775-18-6
    Price: $318/10mg
    Cannabisin P

    Catalog No: CFN95456
    CAS No: 2756983-19-2
    Price: $318/5mg
    erythro-Austrobailignan-6

    Catalog No: CFN95501
    CAS No: 114127-24-1
    Price: $318/10mg
    Ganoweberianic acid E

    Catalog No: CFN95504
    CAS No: 1309931-90-5
    Price: $413/5mg
    Regaloside I

    Catalog No: CFN95525
    CAS No: 126239-78-9
    Price: $318/5mg